SCHEMBL884697

SCHEMBL884697

CNC(=O)c1cccc(Nc2ncccc2CC(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 9/20 0.47
SCN9A Q15858 2/20 0.44
PTK2 Q05397 1/20 0.43
KCNH2 Q12809 2/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
KIT P10721 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
KDR P35968 1/20 0.41
HTT P42858 1/20 0.40
GPR132 Q9UNW8 1/20 0.40
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
PRKCA P17252 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884875 0.80 KCNA5 (0.56) KCNA5KCNH2
SCHEMBL884975 0.80 KCNA5 (0.52) KCNA5KCNH2KDR
SCHEMBL884979 0.80 KCNA5 (0.48) KCNA5PTK2KCNH2
SCHEMBL885048 0.79 KCNA5 (0.56) KCNA5KCNH2
SCHEMBL884491 0.77 KCNA5 (0.52) KCNA5KCNH2LMNAHTT
SCHEMBL884733 0.77 KCNA5 (0.53) KCNA5KCNH2CSNK2A2CSNK2BCSNK2A1
SCHEMBL884558 0.77 KCNA5 (0.51) KCNA5KCNH2LMNA
SCHEMBL884464 0.77 KCNA5 (0.56) KCNA5KCNH2
SCHEMBL884797 0.76 KCNA5 (0.46) KCNA5KCNH2
SCHEMBL884325 0.75 MTOR (0.46) KCNA5PTK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885SCN9A 80/4885PTK2 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.